Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

4 Of The Best Income Stocks Around: GlaxoSmithKline plc, Standard Life Plc, SSE PLC And Centrica plc

GlaxoSmithKline plc (LON: GSK), Standard Life Plc (LON: SL), SSE PLC (LON: SSE) and Centrica PLC (LON:CNA) are four of the best dividend plays around.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Standard Life (LSE: SL) has transformed itself into an income champion over the past five years. The company’s shift to a fee-based business model has led to a tripling of cash flow generated from operations since 2010. Assets under management have risen by 50% over the same period. 

This growth has helped support the company’s dividend payout growth. Since 2011 Standard’s dividend payout has increased at a steady rate of 7% per annum. Since 2010 Standard Life has returned 147p per share to investors, including the recent special dividend and over five years the shares have produced a total return of 180%. Based on the estimated growth of the UK pension market, the next five years could see a similar performance. 

Standard Life trades at a forward P/E of 16.8 and supports a yield of 4.6%. Earnings per share are predicted to grow by 48% this year. 

Dividend concerns 

GlaxoSmithKline’s (LSE: GSK) shares have sunk to a four-year low on fears about the sustainability of the company’s dividend payout. However, to a certain extent, these concerns are unfounded.

Management has stated that the company’s dividend of 80p per share is safe for the next three years. A special dividend of 20p per share payable during the fourth quarter will take the total payout for 2015 to 100p per share, a yield of 7.9% based on Glaxo’s current share price. 

Glaxo currently trades at a forward P/E of 16.9 and supports a yield of 7.2%. Earnings per share are predicted to shrink by 21% this year. 

Slow and steady 

Last year, SSE (LSE: SSE) made a commitment to target an increase in the full-year dividend for 2015/16 of at least RPI inflation, with annual increases thereafter of at least RPI inflation also being targeted.

This is hardly the most impressive dividend policy. The RPI measure of inflation has averaged 1% this year, so investors won’t see much in the way of a dividend increase at all. 

Nevertheless, for the conservative dividend investor SSE’s dividend policy is ideal. The payout is covered 1.2 times by earnings per share and due to the nature of SSE’s business, the company has a certain degree of clarity over its revenue streams. As a result, it’s unlikely management will suddenly take an axe to the dividend. 

SSE currently trades at a forward P/E of 12.6 and supports a yield of 6.2%. Earnings per share are predicted to shrink by 10% this year.

Changing business model 

Centrica (LSE: CNA) has already cut its dividend payout once this year. However, according to City projections the new, lower payout is now covered one-and-a-half times by earnings per share, leaving plenty of room for manoeuvre. 

What’s more, management’s recent decision to scale back Centrica’s upstream business is a great move for the company. Oil & gas production is a notoriously volatile and capital intensive business. Focusing on the more predictable customer-facing side of the business should put Centrica back on the path to long-term sustainable growth.

Also, Centrica’s focus on the more predictable customer side of the business should help the company maintain and increase its dividend over time.  

Centrica currently trades at a forward P/E of 12.5 and supports a yield of 5.4%. Earnings per share are predicted to shrink by 7% this year.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended Centrica and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Up 136%, is this under-the-radar growth stock the UK’s hottest opportunity for 2026?

Amcomri has only been on the market a year, but it’s been one of the UK’s top growth stocks and…

Read more »

Senior couple are walking their dog through a public park in Autumn.
Investing Articles

If a 30-year-old puts £500 a month in a SIPP, by retirement, they’d have…

Worried about not having enough money to retire on? Regularly investing in a Self-Invested Personal Pension (SIPP) may be worth…

Read more »

Investing Articles

Should I sell my Rolls-Royce shares in 2026?

This writer is wondering what to do with his Rolls-Royce shares after an incredible three-year run. Is it finally time…

Read more »

ISA coins
Investing Articles

Here’s how to aim for a £10k second income using an ISA

Zaven Boyrazian shows how a long-term investing strategy can help build a sizable portfolio and even unlock a £10,000+ income…

Read more »

Group of friends meet up in a pub
Investing Articles

Could this FTSE 100 stock be the next to make a 200% gain in one year?

Mark Hartley examines the spectacular recovery of one of the fastest growing stocks on the FTSE 100 and identifies a…

Read more »

Couple working from home while daughter watches video on smartphone with headphones on
Investing Articles

Investing £500 a month in this income stock during 2025 unlocked a passive income of…

Want to make money while sleeping? Here's how much investors could have earned by drip-feeding £500 each month into this…

Read more »

Investing Articles

After a stellar year will Lloyds, NatWest, and Barclays shares crash to earth in 2026?

High-flying Lloyds, NatWest, and Barclays shares have made investors fortunes over the last few years. Harvey Jones now asks: how…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

Warren Buffett has $94.2bn invested in these two stocks!

Warren Buffett and his team have invested a massive amount of money into just two stocks. Should investors think about…

Read more »